Compare ZCMD & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZCMD | LEXX |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 6.7M |
| IPO Year | 2019 | 2011 |
| Metric | ZCMD | LEXX |
|---|---|---|
| Price | $0.94 | $4.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 61.8K | 49.8K |
| Earning Date | 12-22-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $705,923.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6,915.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 52.05 |
| 52 Week Low | $0.02 | $0.35 |
| 52 Week High | $11.96 | $21.60 |
| Indicator | ZCMD | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 39.36 | 56.28 |
| Support Level | $0.72 | $2.67 |
| Resistance Level | $1.03 | $10.26 |
| Average True Range (ATR) | 0.10 | 0.42 |
| MACD | -0.05 | 0.25 |
| Stochastic Oscillator | 16.01 | 87.70 |
ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.